Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society
Neurologia i Neurochirurgia Polska · 2024
DOI: 10.5603/pjnns.102356 ↗Kurz gefasst
Leitlinie in der Zeitschrift Neurologia i Neurochirurgia Polska, 2024. Verfasst von Alina Kułakowska und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Bialystok, Bialystok, Poland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Neurology. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
The treatment of multiple sclerosis (MS) has undergone significant changes since the first disease-modifying therapy (DMT) drug was introduced. Currently, 19 original DMT drugs are registered in the European Union. The choice of optimal therapy is becoming increasingly challenging in the absence of reliable biomarkers on the basis of which disease progression and prognosis can be determined. In addition, longer availability and a growing number of drugs used in MS mean that doctors and patients may have to change therapy when the treatment is ineffective or is associated with the occurrence of adverse effects. The ageing of the MS population, comorbidities, and administration of other drugs during DMT should also be considered. This paper presents recommendations for initiating, monitoring, changing and possibly discontinuing DMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland. dmirowska@wum.edu.pl.
- Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
- Collegium Medicum Jan Kochanowski University of Kielce, Kielce, Poland.
- Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland.
ORCID-Profile: Dagmara Mirowska-Guzel
Zitieren
APA
Kułakowska, A., Mirowska-Guzel, D., Kalinowska, A., Bartosik-Psujek, H., Brola, W., Stasiolek, M., Głąbiński, A., Losy, J., Potemkowski, A., Rejdak, K., Sarzyńska-Długosz, I., Siger, M., Stępień, A., Wawrzyniak, S., Zaborski, J., Zakrzewska-Pniewska, B., & Adamczyk-Sowa, M. (2024). Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.102356
Vancouver
Kułakowska A, Mirowska-Guzel D, Kalinowska A, Bartosik-Psujek H, Brola W, Stasiolek M, et al. Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society. Neurologia i Neurochirurgia Polska. 2024. doi:10.5603/pjnns.102356
BibTeX
@article{Kuakowska2024,
author = {Kułakowska, Alina and Mirowska-Guzel, Dagmara and Kalinowska, Alicja and Bartosik-Psujek, Halina and Brola, Waldemar and Stasiolek, Mariusz and Głąbiński, Andrzej and Losy, Jacek and Potemkowski, Andrzej and Rejdak, Konrad and Sarzyńska-Długosz, Iwona and Siger, Małgorzata and Stępień, Adam and Wawrzyniak, Sławomir and Zaborski, Jacek and Zakrzewska-Pniewska, Beata and Adamczyk-Sowa, Monika},
title = {Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society},
journal = {Neurologia i Neurochirurgia Polska},
year = {2024},
doi = {10.5603/pjnns.102356}
}
EUVIMED